Anzeige
Mehr »
Login
Dienstag, 16.04.2024 Börsentäglich über 12.000 News von 689 internationalen Medien
Biotech-Perle kurz vor entscheidender Meilenstein-Meldung!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
50 Leser
Artikel bewerten:
(0)

Cardiac Science Launches its New Powerheart G5 AED

- Major EU Markets Gain Access to New Product

MANCHESTER, England, June 14, 2012 /PRNewswire/ --Cardiac Science Corporation, a global leader in automated external defibrillators (AED), has launched Powerheart® G5, the next-generation AED to help save lives from sudden cardiac arrest (SCA). SCA - a condition in which the heart suddenly stops beating due to irregularities in its electrical system - strikes as many as 700,000 Europeans annually with the majority of cases being fatal, according to the European Resuscitation Council.

To view the multimedia assets associated with this release, please click: http://www.multivu.com/mnr/54404-powerheartg5aed/

Cardiac Science's new device, now in its fifth generation, is the first AED to combine real-time cardiopulmonary resuscitation (CPR) guidance, customised patient therapy and fast shock times. It is designed to enable both professional rescuers and first-time users to swiftly provide effective, life-saving therapy to aid a person who has suffered SCA.

"Cardiac Science has been working to reduce SCA fatalities since we introduced the first fully automated external defibrillator," said Neal Long, Cardiac Science president and chief executive officer. "By providing intuitive guidance and automatically delivering fast, customised therapy, the Powerheart G5 gives the SCA victim the best chance of a favourable outcome."

The Powerheart G5's major features include:

Ease of Use. Even first-time users can successfully perform each step of a rescue with intuitive, user-paced instruction and real-time CPR feedback. Dual-language options enable almost anyone to respond in an emergency; languages include English, French, Dutch and Danish.

Advanced Patient Care. The G5 automatically assesses the patient's therapy needs and delivers customised shock at an appropriate energy level. The G5 is the first AED to combine fast shock times and customised energy delivery, delivering a higher energy, post-CPR shock in less than 10 seconds (typically) for the best chance at a favourable outcome.

Reliability. The G5 features military-grade construction and an IP55 rating for use in harsh and demanding environments.

The Powerheart G5 AED is not available in all countries. Please check for local availability.

About Cardiac Science
Cardiac Science, an Opto Cardiac Care Ltd. company, develops, manufactures, and markets a family of advanced diagnostic and therapeutic cardiology devices and systems, including automated external defibrillators (AED), electrocardiograph devices (ECG/EKG), cardiac stress treadmill and systems, PC-based diagnostic workstations, Holter monitoring systems, hospital defibrillators, vital signs monitors, cardiac rehabilitation telemetry systems, and cardiology data management systems (informatics) that connect with hospital information (HIS) and other information systems. For information, call 425.402.2000 or visithttp://www.powerheartg5.com/.

Media Contact

Kurt Lemvigh
Cardiac Science
+44-161-926-0000
klemvigh@cardiacscience.com

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2012 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.